These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9175618)

  • 21. The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist.
    Singh L; Field MJ; Hughes J; Menzies R; Oles RJ; Vass CA; Woodruff GN
    Br J Pharmacol; 1991 Sep; 104(1):239-45. PubMed ID: 1686205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholecystokinin receptors do not mediate the behavioral effects of lipopolysaccharide in mice.
    Bluthé RM; Michaud B; Kelley KW; Dantzer R
    Physiol Behav; 1997 Aug; 62(2):385-9. PubMed ID: 9251984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice.
    Hendrie CA; Neill JC; Shepherd JK; Dourish CT
    Physiol Behav; 1993 Oct; 54(4):689-93. PubMed ID: 7902586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attenuation of CCK-induced aversion in rats on the elevated x-maze by the selective 5-HT1A receptor antagonists (+) WAY100135 and WAY100635.
    Bickerdike MJ; Fletcher A; Marsden CA
    Neuropharmacology; 1995 Jul; 34(7):805-11. PubMed ID: 8532148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Similar anxiolytic-like effects following intra-amygdala infusions of benzodiazepine receptor agonist and antagonist: evidence for the release of an endogenous benzodiazepine inverse agonist in mice exposed to elevated plus-maze test.
    Barbalho CA; Nunes-de-Souza RL; Canto-de-Souza A
    Brain Res; 2009 Apr; 1267():65-76. PubMed ID: 19268657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors.
    Gully D; Fréhel D; Marcy C; Spinazzé A; Lespy L; Neliat G; Maffrand JP; Le Fur G
    Eur J Pharmacol; 1993 Feb; 232(1):13-9. PubMed ID: 7681406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracerebroventricular cholecystokinin A-receptor antagonist does not reduce satiation by endogenous CCK.
    Brenner LA; Ritter RC
    Physiol Behav; 1998 Feb; 63(4):711-6. PubMed ID: 9523920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Behavioral effects of the cyclic cholecystokinin peptide analogue JMV-320.
    Hadjiivanova C; Kehayov R; Petkov VV; Amblard M; Martinez J
    Peptides; 1995; 16(5):815-9. PubMed ID: 7479320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence that CCKB receptors mediate the regulation of exploratory behaviour in the rat.
    Harro J; Vasar E
    Eur J Pharmacol; 1991 Feb; 193(3):379-81. PubMed ID: 2055248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of the hypothalamic-pituitary-adrenal axis in food-deprived rats by a CCK-A receptor antagonist.
    Ruiz-Gayo M; Garrido MM; Fuentes JA
    Br J Pharmacol; 2000 Mar; 129(5):839-42. PubMed ID: 10696079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cholecystokinin receptors mediate the development of a preference for the mother by newly born lambs.
    Nowak R; Goursaud AP; Lévy F; Orgeur P; Schaal B; Belzung C; Picard M; Meunier-Salaün MC; Alster P; Uvnäs-Moberg K
    Behav Neurosci; 1997 Dec; 111(6):1375-82. PubMed ID: 9438806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling.
    Klodzinska A; Tatarczyńska E; Chojnacka-Wójcik E; Nowak G; Cosford ND; Pilc A
    Neuropharmacology; 2004 Sep; 47(3):342-50. PubMed ID: 15275823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats.
    Charrier D; Dangoumau L; Puech AJ; Hamon M; Thiébot MH
    Psychopharmacology (Berl); 1995 Sep; 121(1):127-34. PubMed ID: 8539337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ethological analysis of cholecystokinin (CCKA and CCKB) receptor ligands in the elevated plus-maze test of anxiety in mice.
    Johnson NJ; Rodgers RJ
    Psychopharmacology (Berl); 1996 Apr; 124(4):355-64. PubMed ID: 8739551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of CCK1 and CCK2 receptor blockade on amphetamine-stimulated exploratory behavior and sensitization to amphetamine.
    Alttoa A; Harro J
    Eur Neuropsychopharmacol; 2004 Aug; 14(4):324-31. PubMed ID: 15163443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats.
    Przegaliński E; Tatarczyńska E; Chojnacka-Wójcik E
    Neuropharmacology; 2000 Jul; 39(10):1858-64. PubMed ID: 10884566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat.
    Pellow S; File SE
    Pharmacol Biochem Behav; 1986 Mar; 24(3):525-9. PubMed ID: 2871560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety.
    Singh L; Lewis AS; Field MJ; Hughes J; Woodruff GN
    Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1130-3. PubMed ID: 1996314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CCK1 and CCK2 receptors regulate gastric pepsinogen secretion.
    Blandizzi C; Lazzeri G; Colucci R; Carignani D; Tognetti M; Baschiera F; Del Tacca M
    Eur J Pharmacol; 1999 May; 373(1):71-84. PubMed ID: 10408253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists.
    Varty GB; Cohen-Williams ME; Morgan CA; Pylak U; Duffy RA; Lachowicz JE; Carey GJ; Coffin VL
    Neuropsychopharmacology; 2002 Sep; 27(3):371-9. PubMed ID: 12225694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.